The Team

Gaël Roue

Tenure-Track Investigator at Carlos III Health Institute (ISCIII).

Our objective

The final objective of their work is the design of individualized therapies, as it is intended that the information obtained can serve for the conduct of phase I/II clinical trials, in partnership with the biotechnology companies and the hemathology departments associated to their projects.

The project "New therapies against oncogenes and tumoral microenvironment in B-cell aggressive lymphomas" is funded by the Carlos III Health Institute (ISCIII).

A large amount of data from several gene expression analysis techniques and tumor groups was gathered.

To identify the best genetic biomarkers to classify the different groups, we needed to automatically integrate all these data sets.

This integrative approach was not easily available in the classical analysis software tools, at least in an efficient manner.

Which Was The Contribution Of ?

helped them to unveil gene signatures with high biological and clinic significance in their cancer models.